These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26797214)

  • 1. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
    Calderón MM; Penzak SR; Pau AK; Kumar P; McManus M; Alfaro RM; Kovacs JA
    Clin Infect Dis; 2016 Apr; 62(8):1036-1042. PubMed ID: 26797214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
    Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
    Tadesse WT; Adankie BT; Shibeshi W; Amogne W; Aklillu E; Engidawork E
    PLoS One; 2022; 17(1):e0262604. PubMed ID: 35045105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
    Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
    Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
    Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
    BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
    J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
    Mollan K; Daar ES; Sax PE; Balamane M; Collier AC; Fischl MA; Lalama CM; Bosch RJ; Tierney C; Katzenstein D;
    J Infect Dis; 2012 Dec; 206(12):1920-30. PubMed ID: 23148287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
    Tanaka H; Arai M; Tomoda Y; Wada T; Yago K; Satoh M
    J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.